Results 171 to 180 of about 115,987 (377)

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once‐weekly semaglutide vs. dulaglutide.
Xi Tan, Yuanjie Liang, Lin Xie, Joanna Harton, Cynthia Gutierrez, Chalak Muhammad, Caroline Swift, Adam de Havenon   +7 more
wiley   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Sulfonylurea prescription patterns in elderly patients with type 2 diabetes mellitus: A comprehensive analysis of real‐world data from pharmacies in Japan

Journal of Diabetes Investigation
Aims/Introduction The study aim was to investigate sulfonylurea prescription patterns in elderly patients (age ≥65 years) with type 2 diabetes mellitus in Japan. Sulfonylurea use among older adults has been insufficiently examined, despite the associated
Michiko Yamazaki, Tohru Takebe, Masaya Hosokawa, Tomoya Saika, Yutaka Nakao, Shunya Ikeda, Masaya Sakamoto   +6 more
doaj   +1 more source

Correction: Dynamic properties of dipeptidyl peptidase III from Bacteroides thetaiotaomicron and the structural basis for its substrate specificity – a computational study

, 2017
Marko Tomin, Sanja Tomić
openalex   +2 more sources

Dipeptidyl peptidase-4 inhibitor improves glycemic variability in multiple daily insulin-treated type 2 diabetes: a prospective randomized-controlled trial

, 2021
Fukumi Yoshikawa, Hiroshi Uchino, Tomoko Nagashima, Shuki Usui, Masahiko Miyagi, Yukio Ando, Takahisa Hirose   +6 more
openalex   +2 more sources

Prevalence of new‐onset diabetes following COVID‐19 infection: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aim To estimate the prevalence of new‐onset diabetes in adults (≥ 18 years) following SARS‐CoV‐2 infection. Materials and Methods This meta‐analysis includes studies written in English that measured the number of adults (≥ 18 years) diagnosed with diabetes following SARS‐CoV‐2 infection.
Jordan N. Keels, Rose D. LaPlante, Christopher S. Lee, Andrew A. Dwyer   +3 more
wiley   +1 more source

Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]

Diabetes Obes Metab
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB.   +5 more
europepmc   +2 more sources

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database

, 2019
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, C. Esnault, Yujin Shuto, Hiroshi Maegawa, Daisuke Koya   +8 more
openalex   +1 more source